Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.34% | 37.78% | 35.88% | 26.97% | 22.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.17% | 37.79% | 38.89% | 43.46% | 49.01% |
| Operating Income | -28.17% | -37.79% | -38.89% | -43.46% | -49.01% |
| Income Before Tax | -30.05% | -38.01% | -33.60% | -38.98% | -42.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.05% | -38.01% | -33.60% | -38.98% | -42.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.05% | -38.01% | -33.60% | -38.98% | -42.67% |
| EBIT | -28.17% | -37.79% | -38.89% | -43.46% | -49.01% |
| EBITDA | -28.37% | -38.13% | -38.97% | -43.15% | -48.26% |
| EPS Basic | -1.46% | -0.86% | 7.98% | -5.65% | -14.05% |
| Normalized Basic EPS | -1.47% | -0.87% | 7.96% | -5.66% | -14.05% |
| EPS Diluted | -1.46% | -0.86% | 7.98% | -5.65% | -14.05% |
| Normalized Diluted EPS | -1.47% | -0.87% | 7.96% | -5.66% | -14.05% |
| Average Basic Shares Outstanding | 25.63% | 35.10% | 45.02% | 34.08% | 27.96% |
| Average Diluted Shares Outstanding | 25.63% | 35.10% | 45.02% | 34.08% | 27.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |